CSIMarket
 


Alpine Immune Sciences Inc   (ALPN)
Other Ticker:  
 

Alpine Immune Sciences Inc 's Tangible Leverage Ratio

ALPN's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to repayements of liabilities of -34.22% Alpine Immune Sciences Inc improved Tangible Leverage Ratio in forth quarter 2023 to 0.16, below the company's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 37 other companies have achieved lower Tangible Leverage Ratio than Alpine Immune Sciences Inc in the IV Quarter 2023. While Tangible Leverage Ratio total ranking has improved so far in the forth quarter 2023 to 154, from total ranking in the third quarter 2023 at 931 .

Explain Tangible Leverage Ratio?
What is ALPN Market Share?
What are ALPN´s Total Liabilities?


ALPN Tangible Leverage Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity Change 82.78 % -11.2 % 70.18 % 46.88 % 48.4 %
Y / Y Total Liabilities Change -51.61 % -27.99 % -28.24 % -21.9 % -20.54 %
Tangible Leverage Ratio MRQ 0.16 0.49 0.49 0.55 0.6
ALPN's Total Ranking # 154 # 931 # 1027 # 1127 # 1358
Seq. Tangible Equity Change 102.89 % -4.58 % -0.09 % -5.5 % -1.42 %
Seq. Total Liabilities Change -34.22 % -5.43 % -9.84 % -13.71 % -2.12 %



Tangible Leverage Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 38
Healthcare Sector # 66
Overall Market # 153


Tangible Leverage Ratio Statistics
High Average Low
5.33 0.69 0.05
(Jun 30 2020)   (Sep 30 2015)




Financial Statements
Alpine Immune Sciences Inc 's Tangible Equity $ 328 Millions Visit ALPN's Balance sheet
Alpine Immune Sciences Inc 's Total Liabilities $ 52 Millions Visit ALPN's Balance sheet
Source of ALPN's Sales Visit ALPN's Sales by Geography


Cumulative Alpine Immune Sciences Inc 's Tangible Leverage Ratio

ALPN's Tangible Leverage Ratio for the trailling 12 Months

ALPN Tangible Leverage Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Tangible Equity TTM Growth 82.78 % -11.2 % 70.18 % 46.88 % 48.4 %
Y / Y Total Liabilities TTM Growth -51.61 % -27.99 % -28.24 % -21.9 % -20.54 %
Tangible Leverage Ratio TTM 0.37 0.53 0.56 0.68 0.78
Total Ranking TTM # 6 # 932 # 13 # 6 # 1
Seq. Tangible Equity TTM Growth 102.89 % -4.58 % -0.09 % -5.5 % -1.42 %
Seq. Total Liabilities TTM Growth -34.22 % -5.43 % -9.84 % -13.71 % -2.12 %


On the trailing twelve months basis Due to repayements of liabilities of -34.22% Alpine Immune Sciences Inc decreased Tangible Leverage Ratio in the 12 months ending in IV Quarter 2023 to 0.37, above the Alpine Immune Sciences Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry ALPN recorded the lowest Tangible Leverage Ratio. While Tangible Leverage Ratio total ranking has improved so far to 6, from total ranking in previous 12 month period at 932.

Explain Tangible Leverage Ratio?
What is ALPN Market Share?
What are ALPN´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 6


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.28 0.1 0
(Jun 30 2020)   (Dec 31 2023)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Tangible Equity
Catalyst Pharmaceuticals Inc   0.42 $ 82.233  Millions$ 193.832  Millions
Biomarin Pharmaceutical Inc  0.42 $ 1,890.054  Millions$ 4,460.649  Millions
Salarius Pharmaceuticals inc   0.41 $ 2.192  Millions$ 5.287  Millions
Avenue Therapeutics Inc   0.41 $ 0.268  Millions$ 0.654  Millions
Oncolytics Biotech Inc   0.41 $ 8.623  Millions$ 21.113  Millions
Anaptysbio Inc   0.40 $ 35.665  Millions$ 88.103  Millions
Arcus Biosciences Inc   0.40 $ 184.000  Millions$ 462.000  Millions
Integrated Biopharma Inc  0.39 $ 7.155  Millions$ 18.566  Millions
Benitec Biopharma Inc   0.38 $ 5.883  Millions$ 15.470  Millions
Context Therapeutics Inc   0.35 $ 4.192  Millions$ 11.871  Millions
Kamada Ltd   0.34 $ 83.972  Millions$ 244.021  Millions
Kronos Bio Inc   0.34 $ 54.201  Millions$ 159.078  Millions
Vertex Pharmaceuticals Inc  0.33 $ 5,149.800  Millions$ 15,652.500  Millions
Abcellera Biologics Inc   0.32 $ 316.818  Millions$ 984.087  Millions
Anebulo Pharmaceuticals Inc   0.31 $ 2.027  Millions$ 6.487  Millions
Zai Lab Limited  0.31 $ 240.177  Millions$ 782.729  Millions
Deciphera Pharmaceuticals Inc   0.28 $ 96.771  Millions$ 350.916  Millions
Zymeworks Inc   0.27 $ 116.074  Millions$ 427.506  Millions
Igc Pharma Inc   0.27 $ 2.091  Millions$ 7.871  Millions
Zentalis Pharmaceuticals Inc   0.26 $ 114.404  Millions$ 433.655  Millions
Praxis Precision Medicines Inc   0.26 $ 18.279  Millions$ 69.669  Millions
Aadi Bioscience Inc   0.26 $ 27.228  Millions$ 105.195  Millions
Avidity Biosciences Inc   0.26 $ 127.791  Millions$ 500.764  Millions
Aclaris Therapeutics Inc   0.25 $ 39.800  Millions$ 156.910  Millions
Procyon Corporation  0.25 $ 0.583  Millions$ 2.335  Millions
Prothena Corporation Public Limited Company  0.24 $ 135.017  Millions$ 561.365  Millions
Aurinia Pharmaceuticals Inc   0.24 $ 88.099  Millions$ 372.977  Millions
Regeneron Pharmaceuticals Inc   0.23 $ 5,801.500  Millions$ 24,934.500  Millions
Intra cellular Therapies Inc   0.23 $ 136.871  Millions$ 591.424  Millions
Corcept Therapeutics Inc  0.23 $ 114.812  Millions$ 506.705  Millions

Date modified: 2024-03-20T23:16:29+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com